Epitalon: What the Evidence Shows, and What FDA Found

Epitalon (also spelled epithalon) is a four-amino-acid peptide, Ala-Glu-Asp-Gly, sold online as an anti-aging and telomere peptide. Nearly all of the research on it comes from one group in St. Petersburg, Russia, led by Vladimir Khavinson. The telomere claim rests on cell-culture work, first from that group in 2003 and repeated by a British lab in 2025.^[7][9] The often-quoted drops in death rates among elderly people were not seen with epitalon. They come from studies of epithalamin, a cattle pineal-gland extract, which FDA treats as a different substance.^[1] When FDA reviewed epitalon in 2026, it found no clinical data on its safety in people.^[1] Epitalon is not approved anywhere FDA checked, and it is not on the list of ingredients US pharmacies may compound with.

What epitalon is, and what it is not

Epitalon is a synthetic tetrapeptide: alanine, glutamic acid, aspartic acid and glycine, chained in that order. Khavinson’s group designed it by analyzing the amino-acid makeup of epithalamin, a polypeptide extract made from the pineal glands of cattle that the same researchers had studied since the 1980s.^[1][18] FDA’s review describes epitalon as a “synthetic analog” of epithalamin, but is explicit that the agency “considers epitalon and epithalamin as different substances.”^[1]

That distinction is the most important fact on this page. An extract is a mixture of many molecules, and a result found with it cannot simply be credited to one four-amino-acid chain chosen from it. Sales pages blur the two all the time. Even the pharmacy nomination packet FDA reviewed credited a 28% fall in mortality to “epithalon,” when the study behind it tested epithalamin.^[1][11]

The epitalon evidence, sorted by what was tested

The telomerase claim: real in a dish, untested in a person

Telomeres are protective caps on the ends of chromosomes. They shorten each time most cells divide, and when they get too short the cell stops dividing. Telomerase is the enzyme that rebuilds them. Most adult body cells keep it switched off.

In 2003, Khavinson and two colleagues reported that adding epitalon to human fetal lung fibroblasts, a cell type that normally has no telomerase activity, switched on the enzyme and lengthened the cells’ telomeres.^[7] A follow-up a year later took the same kind of cells to the point where untreated cultures stopped dividing, at the 34th passage. The epitalon-treated cells, the group reported, went on for 10 more divisions and kept going.^[8] Both are short reports in the English edition of a Russian journal.

For more than twenty years nobody outside that circle published a careful test of the claim. In 2025 a team at Brunel University London did. Using epitalon bought from a commercial peptide supplier, they treated normal human fibroblasts and breast epithelial cells for three weeks and two breast-cancer cell lines for four days. Telomeres grew longer in the normal cells, along with higher telomerase gene expression and enzyme activity. In the cancer cells, telomeres also lengthened, partly through a telomerase-independent mechanism known as ALT.^[9] The authors list the main limitation themselves: it was a study of cells in flat lab cultures, not of animals or people.^[9]

That is an important replication, and it cuts both ways. It supports the cell-level finding the whole “telomere peptide” pitch rests on. It also shows epitalon lengthening telomeres in cancer cells, which is exactly what worried FDA’s reviewers:

“From the mechanistic standpoint, epitalon has the potential to be carcinogenic. Specifically, epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer.”^[1]

— FDA Briefing Document, Epitalon, PCAC July 23–24, 2026

Longer telomeres in a dish do not mean a longer life for the person the cells came from. No study has measured telomere length in people who took epitalon, and none has shown that changing it improves any health outcome.

The elderly mortality studies: an extract, not epitalon

The figures most often quoted for epitalon come from studies of older adults run in St. Petersburg and Kyiv, in Ukraine. All of them tested epithalamin, the cattle-gland extract.

• 266 older adults, 6–8 years. Khavinson and Morozov reported that people given epithalamin or a thymus extract, thymalin, for the first two to three years had fewer respiratory infections and less heart disease than controls. Death rates were 1.6 to 1.8 times lower with epithalamin, and 4.1 times lower in a group given both extracts every year for six years.^[10]
• Older coronary patients, 12 and 15 years. A Kyiv team, with Khavinson as co-author, gave older heart patients courses of epithalamin on top of usual care. At 12 years, it reported 28% fewer deaths in the epithalamin group than in controls, and half the cardiovascular deaths.^[11] Its 15-year report describes 39 patients given six courses over three years against 40 on usual care alone, and again reports significantly lower mortality.^[12]

PubMed tags these papers as randomized trials, and the Kyiv reports call themselves randomized. We have read them only as English abstracts. None of the abstracts describes how patients were assigned, whether anyone was blinded, or how deaths were counted. Those are the details that decide whether a mortality result is trustworthy. The groups are also small for a death-rate endpoint: in a trial of about 80 people, a handful of deaths either way changes the percentage a great deal. No outside group has repeated any of these studies.

What the animal lifespan studies actually found

The cleanest test of epitalon itself on lifespan is a 2003 mouse study from the same group. Female mice got 1 microgram under the skin for five days every month, from three months of age until they died, with 54 animals in each group. Epitalon did not change average life span. It extended the life span of the longest-lived 10% of mice by 13.3%, raised maximum life span by 12.3%, and left the overall tumor rate unchanged, though leukemia was less common.^[13]

FDA’s reviewers noted the limits of this body of work. The studies used a single fixed dose and female mice only. Because dosing was five days a month, the mice were exposed for at most about 22 weeks in total. That is too short and too intermittent to say much about cancer risk from regular use.^[1]

Epitalon in people: three small studies

FDA searched the literature and found three studies in which the peptide itself, rather than the extract, was given to humans.^[1]

• Retinitis pigmentosa, 2002. Epitalon injected next to the eye in patients with inherited retinal degeneration. The abstract reports a positive effect in 90% of cases but gives no patient count or comparison group.^[14] Epitalon received a US orphan-drug designation for the disease in 2010, which was revoked in 2016.^[1]
• Night-shift workers, 2021. Forty women aged 40 to 50 with low melatonin output got a sublingual epitalon spray or saline twice a day for 20 days. A melatonin breakdown product in urine rose 1.7-fold with epitalon and not with placebo. FDA notes the paper did not say whether the study was blinded, did not measure sleep, and reported no safety data.^[1]
• Clock genes, 2021. A related report from the same project measured circadian gene activity in blood cells.^[1]

That is the whole human record for epitalon: small, short, with blinding unreported, and all from the developer’s circle. FDA’s searches of PubMed, Embase and ClinicalTrials.gov found no clinical study assessing epitalon’s safety, and no pharmacokinetic data in people.^[1] ClinicalTrials.gov lists no registered trial of epitalon, epithalon or epithalamin.

Melatonin and sleep: the use FDA actually reviewed

The pharmacies that nominated epitalon proposed it as an injection for insomnia, and that is the only use FDA evaluated.^[1] The case rests on melatonin. In old rhesus monkeys, ten days of epitalon injections raised evening melatonin levels more than fourfold.^[1] A French study run with the St. Petersburg group, however, found that epitalon added directly to rat pineal glands in the lab had no effect on melatonin release, in young or old animals.^[15]

FDA found no animal study measuring epitalon’s effect on sleep itself and no study in people with insomnia. Its reviewers concluded there is “a lack of evidence to support the effectiveness” of epitalon for insomnia, a condition with several approved treatments.^[1] Our page on DSIP, another “sleep peptide” reviewed at the same meeting, covers similar ground.

How to weigh a literature that comes from one place

FDA’s reviewers put the situation plainly: “Most pharmacological studies of epitalon have been conducted and published by Dr. Khavinson’s research group in Russia.”^[1] A PubMed search returns more than 160 records on the peptide. The large majority carry Khavinson, his long-time collaborator Vladimir Anisimov, or the St. Petersburg Institute of Bioregulation and Gerontology on the author line. Many appeared in Russian journals or their English translations.

Where the research was done is not the problem. The problem is that one team developed the compound, ran nearly every test of it and interpreted every result. Outside work does exist, but it is thin and none of it involves people: the 2025 British cell study, a Chinese study showing epitalon reduced damage in aging mouse egg cells in a dish, and a 2025 Polish review concluding that it “remains uncertain” how the peptide works.^[9][16][18] We applied the same test to selank and semax, which also come almost entirely from Russian research groups.

The telomere result has now been repeated by an outside lab, in cells. The human results have not been repeated by anyone, and they were not about epitalon.

Is epitalon legal? Where it stands in October 2026

FDA reviewed epitalon for the 503A bulks list, the short list of ingredients a state-licensed pharmacy may compound with when a substance has no official monograph and is not part of an approved drug.^[3] Both pharmacy nominations were withdrawn, and FDA reviewed epitalon and epitalon acetate on its own initiative.^[1] Its safety-risk page now carries this note:

“FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.”^[2]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

FDA’s Pharmacy Compounding Advisory Committee took up epitalon for insomnia on July 24, 2026.^[5] FDA has not posted a vote summary. Healio reported that the committee voted 7 to 4, with one abstention, in favor, even though FDA’s staff had recommended against all seven peptides on the agenda.^[6] The vote is advice, not a decision: FDA said it will not issue a final determination until it has weighed the committee’s input, and adding a substance to the list takes formal rulemaking that is expected to run into 2027.^[1][6] As of mid-October 2026 the Federal Register shows no proposed rule naming epitalon. Our guide to whether peptides are legal covers the other peptides voted on that week.

“Research use only” vials and clinic menus

FDA found epitalon sold online in vials from 10 mg to 50 mg, in capsules and as an oral spray, often labeled “for research use only,” and promoted by wellness clinics as “the fountain of youth.”^[1] It could not identify any pharmacy that openly compounds it, and no outsourcing facility has reported making it. FDA’s review also cites a federal case in Kentucky against a pharmacy that compounded and distributed epitalon products between 2018 and 2020.^[1] In 2015, Belgium’s public health institute reported identifying epitalon in two illegal pharmaceutical preparations.^[17]

On the clinic side, of the 153 telehealth sellers in our register with a structured peptide menu, one lists epitalon. None of the 157 FDA warning letters in our warning-letter tracker names epitalon in the text we hold. An absence of letters is not a finding that selling it is lawful.

FDA’s reviewers flagged practical problems for anyone injecting it. Epitalon has no official name standard, different salt forms are sold under the same name, and the certificates of analysis FDA saw did not test for endotoxins, microbial contamination or peptide clumping. Those gaps matter most for an injection.^[1] What is in a vial labeled epitalon depends entirely on who made it. Our explainer on what cannot legally be compounded sets out the rules that apply.

What this means if you are considering epitalon

• The telomere effect has been shown in cells, by the developer’s group and once independently. It has never been measured in a person taking epitalon.
• The mortality and life-extension figures quoted for epitalon come from studies of a different substance, a pineal extract, in small cohorts with little published detail.
• FDA found no clinical data on epitalon’s safety in humans, and its reviewers raised a theoretical cancer concern from the same telomerase mechanism that is marketed as a benefit.
• It is not an approved drug and is not on the 503A list. An advisory vote in its favor has not changed that.
• If you are taking a GLP-1 or any other prescription, tell the prescriber about anything else you inject.

For the wider picture, our review of which clinic peptides have human trials puts epitalon beside the rest of the menu, and the peptides hub profiles the ones with the most evidence.